Opportunity

Simpler Grants.gov #RFA-CA-26-001

NCI Grant for Innovative Technology Development in Cancer Research

Buyer

National Institutes of Health

Posted

September 08, 2025

Respond By

April 10, 2026

Identifier

RFA-CA-26-001

NAICS

541715, 541714

This opportunity from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), seeks grant applications for the development of innovative technologies in cancer research. - Government Buyer: - National Institutes of Health (NIH), National Cancer Institute (NCI) - Scope: - Soliciting early-stage, high-innovation technology development projects - Focus on biospecimen analysis, targeting, probing, handling, and quality control for cancer research and clinical care - Projects may include proof-of-concept and pilot studies - Technologies should accelerate or enhance research in cancer biology, early detection, screening, diagnosis, treatment, cancer control, epidemiology, and health disparities - Products/Services Requested: - No specific products, part numbers, or quantities listed - Applicants are expected to propose new, innovative technologies - OEMs and Vendors: - No OEMs or vendors specified, as this is a grant for technology development - Unique Requirements: - Technologies must be applicable to cancer research - Broad eligibility: small businesses, nonprofits, educational institutions, tribal governments, and federal agencies - Part of the NCI Innovative Molecular Analysis Technologies (IMAT) Program

Description

The National Cancer Institute (NCI) solicits grant applications to develop innovative technologies for analyzing, targeting, probing, handling, or quality control of biospecimens used in cancer research or clinical care. The focus is on early-stage projects proposing proof-of-concept or pilot studies to test feasibility. Applications should demonstrate high technical innovation and potential to enhance research in cancer biology, detection, diagnosis, treatment, control, epidemiology, or health disparities. Technologies must be focused on cancer applications and are part of the NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

View original listing